Search

everythinglearnresearchcommunity

for

Search:↓

The results of using Pyrilutamide, a hair loss treatment available on the gray market, and other treatments such as Minoxidil, Finasteride and RU58841.

The conversation is about expecting results from Breezula, a hair loss treatment, with no new information released as of April 1st. Some joked it's just onion juice, while another comment suggested a conspiracy to cause baldness.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.

A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.

This user has been taking finasteride for several years and recently added topical minoxidil to their regimen, specifically targeting the area of hair loss. They are wondering if this was a wise course of action.

User asks about topical spironolactone experience. Two studies show it as promising anti-androgen treatment, with 5% cream available on Minoxidilmax website.

Exploring the effectiveness of redensyl, a hair loss treatment, compared to minoxidil and finasteride. People shared experiences using redensyl and products containing it, such as The Ordinary Hair Serum.

A user expressed frustration about hair loss and its impact on their 20s, mentioning financial struggles and mental health concerns. Responses included advice on positive thinking, self-improvement, and seeking treatment options like Minoxidil and finasteride.

The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

Using Nizoral shampoo intermittently and reassessing scalp condition after each bottle, potentially adding in other tools to target seb derm, and alternating between Pura D'Or and Nizoral for a healthy and clean scalp.

Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.

User discusses frustration with hair loss treatments and lack of progress. Emphasizes importance of measuring blood hormone levels to understand treatment effectiveness and side effects.

A 26 year old female dealing with hair loss who is considering treatments such as Spiro, minoxidil and finasteride. Other potential solutions mentioned are PRP treatment, a wig, and bio-identical estrogen combined with bica.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

David Barreto shared that a London-based research group is conducting a 12-month trial for a new nutraceutical treatment for pattern hair loss, designed with Dr. Carlos Puig. The trial aims to provide robust data, with results expected in 1-2 years, potentially representing a significant advancement since finasteride’s introduction in 1997.

A 23-year-old male was using 0.5 mg of dutasteride daily, 10% minoxidil twice daily for 4-5 months then once daily, and vitamin D for a month for hair loss treatment but saw a decline in results. It's suggested that the decline may be due to reducing minoxidil application to once a day and a doctor's visit is recommended for further advice.

A gel of keratin microspheres promotes hair follicle growth, showing similar effectiveness to minoxidil in mice. The treatment activates hair growth pathways and reduces inflammation, with potential applications in drug delivery for hair-related disorders.

The user has been using topical finasteride and minoxidil for five months with little progress and is considering oral dutasteride to lower DHT levels, questioning if minoxidil is more effective with reduced DHT. They also use microneedling and tretinoin in their treatment routine.

Hair growth can be induced without stopping DHT, as seen with Minoxidil. HMI115 may work by promoting follicle growth, not targeting the root cause of hair loss (DHT).

User took 0.5mg Finasteride daily and 1x Minoxidil daily for 3 months, experienced positive hair growth and temporary side effects. Recommends sticking with treatment and adjusting dosage if needed.

Pyrilutamide, a drug in phase 3 trials in China, potentially becoming available in late 2023 or early 2024; Finasteride being used as a current treatment for hair loss; and the possibility of joining a group buy for black market versions of Pyrilutamide.

The conversation discusses the use of topical finasteride from Hasson and Wong, with claims that none of their 800 users reported side effects. The user expresses skepticism about these claims and seeks others' experiences with the treatment.

A user's 18-month hairline progress using minoxidil, finasteride, Nizoral, microneedling, and scalp massage. They share their routine and discuss treatment effectiveness and photo order confusion.

The user has been successfully managing hair loss for five years using oral minoxidil and finasteride. They experienced significant improvement and plan to continue the treatment without breaks to maintain results.

A user tried microneedling for hair loss with a Dr. Pen at 0.8 mm and experienced bleeding, questioning if the intensity was too much. Others suggested a less aggressive approach, and one mentioned finasteride as a helpful treatment without side effects.

A user did not respond to finasteride, dutasteride, and oral minoxidil for hair loss after four years of treatment and is considering scalp micropigmentation (SMP). Other users suggest the hair loss pattern may indicate alopecia areata and recommend seeing a dermatologist.